ERBB2 and gastric cancer: Based on CheckMate-649, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with certain types of chemotherapy (XELOX (capecitabine and oxaliplatin) or FOLFOX (leucovorin, fuorouracil, and oxaliplatin)) for the initial treatment of patients with advanced or metastatic GC or GEJC (non-HER2-positive tumors).